|
Drugs (psychoactive) - World Health Organization (WHO)
About 296 million people aged 15-64 had used psychoactive drugs in 2021 and about 39.5 million people are estimated to be affected by drug use disorders (harmful pattern of drug use or drug dependence). It is estimated that about 0.6 million death annually are attributable to drug use with about 420 000 male and 160 000 female deaths.
WHO Drug Information - World Health Organization (WHO)
WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information is published 4 times a year.
Drug use and road safety - World Health Organization (WHO)
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours.
Medicines - World Health Organization (WHO)
The first is regulatory issues, which can affect how medicines are bought to market, create lag times and cause the supply of medicines in some areas of the globe to be delayed long after they are available elsewhere. High prices, misuse of drugs and poor or unreliable drug quality contribute to this issue.
WHO updates guidelines on opioid dependence treatment and overdose ...
Out of 600,000 deaths attributed to drug use, about 450 000 are due to use of opioids according to the latest WHO estimates. It is crucial that people with opioid dependence and those at risk of opioid overdose have access to prevention, harm reduction, treatment, and care, which are of good quality, affordable, ethical and evidence based.
1.3 Drug-resistant TB - World Health Organization (WHO)
Box 1.3.1: Anti-TB drug resistance: data sources and availability. There are two main sources of data about levels of anti-TB drug resistance: national surveys and continuous surveillance (i.e. routine diagnostic testing for drug resistance among people diagnosed with bacteriologically confirmed TB) (4).
2.4 Drug-resistant TB treatment - World Health Organization (WHO)
People with drug-resistant TB (DR-TB) need treatment with regimens that include second-line drugs, such as bedaquiline and fluoroquinolones (1). WHO recommends different regimens for rifampicin-resistant TB (RR-TB) or multidrug-resistant TB (MDR-TB, defined as resistance to both rifampicin and isoniazid); isoniazid-resistant TB; pre-extensively ...
Annex 5 WHO good distribution practices for pharmaceutical products
236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products.
Bacteriophages and their use in combating antimicrobial resistance
In the case of drug-resistant bacteria, phages provide a biologically innovative approach to treating infections that can no longer be treated with traditional antibiotics. However, further evidence from clinical studies is needed before phages can become widely available for routine therapeutic use in humans.
The ATC/DDD Methodology - World Health Organization (WHO)
The definition of the DDD is: The assumed average maintenance dose per day for a drug used for its main indication in adults. The ATC/DDD methodology facilitates the presentation and comparison of drug consumption statistics at international, national and regional levels despite differences in nomenclature (both branded and generic), packing ...
|
1000s of New Jobs